Find New Funds for
Biopharmaceutical
Research and Development

or any of your company’s current priorities through asset management and valuation.

New market research analysis reveals:

  • Only 13.8% of all biopharma drug lines on average are ever approved – wasting a whopping 86.2% of total R&D investment.
  • The traditional drug pricing model is under a bipartisan political and economic attack that will last far beyond 2020.
  • Biopharma companies like yours have recovered $750,000+ in operating costs to fund R&D and other priorities through active asset management and valuation strategies.

I am raw html block.
Click edit button to change this html

Sponsored by the Tiger Liquidity Services Biopharma Partnership